Efficacy of the Janus kinase 1/2 inhibitor ruxolitinib in the treatment of vasculopathy associated with TMEM173-activating mutations in 3 children

Efficacy of the Janus kinase 1/2 inhibitor ruxolitinib in the treatment of vasculopathy associated with TMEM173-activating mutations in 3 children

Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Journal of Allergy and Clinical Immunology - Volume 138, Issue 6, December 2016, Pages 1752-1755

Marie-Louise MD, Mathieu Paul PhD, Nadia PhD, Alexandre MD, PhD, Eric MD, Darragh PhD, Didier MD, Guilhem MD, Gillian I. PhD, Bruno MSc, Anne PharmD, PhD, Nihel MD, Consuelo Modesto MD, Christine MD, PhD, Monique MD, Laureline MD, Muriel MD, Philippe MD,